The Real Message Behind Commercial mRNA Products

Thanks to Jane M. True VP, mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer Part of an absorbing conversation around the topic: Addressing the Next Pandemic Must be Diverse, Reliable, and Sustainable. World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the US goal to design, test, and review a new vaccine just 100 days after a pandemic declaration and to produce enough vaccines for the US and the world in 130 and 200 days. Past preparedness efforts have focused on innovation and reliability—culminating in the novel mRNA vaccines. Today, it’s important to consider diverse responses—and how we can make the investments we make today sustainable and “ready” for when an emergency happens.

The conversation supports a new eBook coming in April on mRNA.

The Real Message Behind Commercial mRNA Products
mRNA-based vaccines have been largely optimized for stability, structure, and delivery. Behind the scenes, fervent activity continues to push at the boundaries for vaccine applications, and also mRNA therapies more generally. Regarding novel delivery in particular, but in tandem with efforts to ramp up (by orders of magnitude) dose loading capabilities, new Intellectual property filings abound. Novel strategies from related fields have been tested, rejected, modified and integrated. Fundamentally, we are at the early stages of unraveling what similarities and differences we can take advantage of for mRNA modalities in oncology, infections disease or CNS indications. The new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns. This eBook will explore the different innovations and challenges in the development and manufacture of mRNA therapies.